Guidelines Address RT for Management of HPV-Linked Oropharyngeal Cancer
By Elana Gotkine HealthDay Reporter
FRIDAY, June 28, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online June 18 in Practical Radiation Oncology, recommendations are presented for the use of radiation therapy (RT) for management of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).
Danielle N. Margalit, M.D., M.P.H., from Brigham and Women's/Dana-Farber Cancer Center in Boston, and colleagues addressed five key questions on the use of RT for management of HPV-associated OPSCC. Recommendations were based on a systematic review of the literature and predefined consensus-building methodology.
The researchers recommended concurrent cisplatin for patients receiving definitive RT with T3 to 4 disease and/or one node >3 cm, or multiple nodes. Concurrent cetuximab, carboplatin/5-fluorouracil, or taxane-based systemic therapy are conditionally recommended for similar patients ineligible for cisplatin. RT with concurrent cisplatin is recommended for positive surgical margins or extranodal extension in the postoperative setting. For pT1 to 2 disease and a single node ≤3 cm, without other risk factors, observation is conditionally recommended. For patients treated with definitive RT with concurrent systemic therapy, 7,000 cGy in 33 to 35 fractions is recommended; 5,600 to 6,000 cGy is recommended for patients receiving postoperative RT without positive surgical margins and extranodal extension. Intensity modulated RT is recommended over three-dimensional techniques for all patients receiving RT, with reduction in dose to critical organs-at-risk. About three months after definitive RT/chemoradiation, reassessment with positron emission tomography-computed tomography is recommended.
"This updated guideline underscores the importance of tailored radiation strategies that maximize patient survival while minimizing side effects," Margalit said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
Past-Year Pap Testing Rates Were Lower in 2022 Than 2019
FRIDAY, June 14, 2024 -- Past-year Papanicolaou testing rates were lower in 2022 than in 2019, overall, and lower rates were seen in rural versus urban women, according to a study...
Recommendations Issued for Palliative RT for Symptomatic Bone Mets
THURSDAY, May 30, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online May 22 in Practical Radiation Oncology...
At-School Vaccination Boosts HPV Vaccination Coverage
THURSDAY, May 30, 2024 -- At-school vaccination may be a useful tool to increase human papillomavirus (HPV) vaccination coverage among adolescents, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.